About

Who We Are

Genesis pairs leading AI researchers and simulation experts with world-class drug hunters to optimize drug discovery and create new medicines, for our partners and our own pipeline. We are supported by world-leading AI and life science investors who share this long-term vision.

Our team

Our AI researchers bring frontier ML experience from the field's leading labs. Our drug hunters bring decades of discovery expertise from major pharma and biotech. Every day, both sides are co-creating the models and medicines.

Management

Evan Feinberg Ph.D.

CEO, Co-founder

Sergey Edunov

CTO

Will McCarthy

COO

Shifeng Pan Ph.D.

CSO

AI / Tech Leads

Drausin Wulsin Ph.D

Sr. Principal ML Research

Maruan Al-Shedivat Ph.D

Sr. Director of ML Research

Andrea Bootsma Ph.D

Director of CADD Science

Steven Kearnes

Research Fellow

Board of Directors & Observers

Guido Appenzeller

a16z

Paul Friedman MD

Independent

Jordan Jacobs

Radical Ventures

Kris Jenner MD D. Phil.

Rock Springs

Peppi Prasit Ph.D.

Independent

Mohamed "Sid" Siddeek

NVentures, NVIDIA

James Watson

a16z

Greg Yap

Menlo Ventures

Our Journey

Unlocking Drug Discovery with Groundbreaking AI

2025

Genesis Unveils Pearl

A generative foundation model for biomolecular structure prediction.

Pearl was demonstrated across rigorous and extensive benchmarking to be the field-leading model for small molecule protein-ligand structure prediction. Pearl features innovative architecture, training methodology, and large-scale synthetic data, and was enabled by our collaboration with NVIDIA.

2024-2025

Gilead & Incyte Partnerships

Genesis announces partnerships with Gilead & Incyte worth $65M upfront across both deals.

Genesis uses its GEMS AI platform to identify and optimize differentiated drug candidates against selected targets, working closely with its partners’ discovery teams. These collaborations amplify the impact of our platform beyond our internal discovery programs.

2023

Series B

Genesis Closes $200M Series B Funding

An oversubscribed round of funding was co-led by a16z and included new investors such as Fidelity, BlackRock, and NVIDIA (NVentures). This capital enables the advancement and expansion of Genesis’ internal pipeline, and further advancement of its field-leading GEMS platform.